We are making the world where everyone can live a healthy and happy life
-
2021
- Granted a license for the management of human cells etc.
- Approval of IND application for Phase 3 clinical trial of Furestem-AD inj by MFDS
- Entered into MOU with Seoul National University Bundang Hospital
- Acquisition of cosmetics business
-
2020
- Obtained a manufacturing license from MFDS for advanced biopharmaceuticals
- Signed MOU for gene and cell therapy research with G+FLAS Life Sciences
-
2019
- Signed exclusive rights for domestic sales of Furestem-AD and technology transfer agreement with HYUNDAI Bioland
-
2018
- Received IND approval for Phase 1/2a clinical trial of Furestem-RA from MFDS
-
2017
- Signed Joint Development Agreement with Germany’s Heraeus Medical GmbH for osteoarthritis stem cell therapy
-
2016
- Nominated for Korea-China Science Technology Collaboration Project – Researching stem cell therapy for neurological disorders targeted for Asians
- Nominated by The Ministry of Trade, Industry and Energy as a "K-BrainPower" company
- Signed stem cell conditioned media joint business contract with Dongwha Pharmaceutical (MOU)
-
2015
- Listed on KOSDAQ
- Concluded the contract of iNSC technology joint business with Orig3n of the U.S
- Expanded the Construction of Stem Cell GMP Center
- Selected for the business in the development of high tech medical technology – Phases 1/2a clinical research for Crohn’ disease
- Acquired ISO certificates (ISO 9001, ISO 14001)
- Selected for the future industry leading technology development business – R&D for cell culture system
- Concluded the joint business contract for the stem cell conditioned medium cosmetics with COSON.
-
2014
- Approved of Furestem-CD® Phase 1 (added psoriasis indicant)
- Concluded a contract for the stem cell therapy sales right and joint development with Daewoong Pharmaceutical Inc
- Selected for the high tech medical technology development business – Occlusive arteriopathy preclinical
- Certified for Technology INNO-BIZ
- Approved of Furestem-RA® Phase 1
-
2013
- Changed business name to Kangstem Biotech
- Selected for the parts material business – GvHD preclinical
- Approved of Furestem-CD® Phases 1 & 2a
- Approved of Furestem-AD® Phases 1 & 2a
-
2012
- Selected for the public health medical research development business - Psoriasis preclinical
- Selected for the public health medical study development business - Crohn’s disease preclinical
- Completed the construction of Stem Cell GMP Center
-
2011
- Selected for the industry & academy cooperative technology transfer business – Atopic Dermatitis preclinical
- Recognized for the company auxiliary research center by KOITA (Korea Industry & Technology Association)
- Certified for the venture company by KIBO (Korea Technology Finance Corporation)
-
2010
- Established Kangstem Holdings
